Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001507499 | SCV001713091 | uncertain significance | not provided | 2020-07-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001507499 | SCV002298612 | uncertain significance | not provided | 2024-01-22 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 32 of the MYO18B protein (p.Val32Ala). This variant is present in population databases (rs200574321, gnomAD 0.1%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with MYO18B-related conditions. ClinVar contains an entry for this variant (Variation ID: 1162878). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV003132509 | SCV003817812 | likely benign | Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome | 2024-01-16 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001507499 | SCV005195330 | uncertain significance | not provided | criteria provided, single submitter | not provided |